Kinnate Biopharma Inc.: key financial figures for fiscal year 2023 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Net Income/Loss (FY2023)
- -$112.6M
- Total Assets (FY2023)
- $173.6M
- Total Equity (FY2023)
- $159.3M
- Cash Flows from Operating Activities (FY2023)
- -$100.0M
Source: Kinnate Biopharma Inc. 10-K filing (FY2023). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
